IXICO PLC

Report Publication Announcement • Nov 3, 2025

National Storage Mechanism | Additional information

RNS Number : 9690F

IXICO plc

03 November 2025

IXICO plc

("IXICO", the "Company" or the "Group")

Capital Markets Day Presentation and Video

03 November 2025 IXICO plc (AIM: IXI) - London, UK. IXICO, a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development in neurological disorders, announces that a recording of the Capital Markets Day held on Thursday 30 October 2025 is now available on the Company's website.

To view the recording and a copy of the presentation, please the see the Investors section of IXICO's website https://ixico.com/investors/company-information/

Bram Goorden, CEO of IXICO, said: "As we presented during the Capital Markets Day, IXICO are well on track to continue delivering double digit topline growth and achieve profitability in the medium term. The future success of IXICO will be defined by the continued evolution and innovation of its AI-tech platform, and partnering this platform with the leading biopharma, data and AI players in the field of neurological precision medicine".

Ends

For further information please contact:

IXICO plc	+44 (0) 20 3763 7499
Grant Nash, Chief Financial Officer James Chandler, Chief Business Officer
Cavendish Capital Markets Limited (Nominated Adviser and Sole Broker)	+44 (0) 20 7220 0500
Giles Balleny (Corporate Finance) Nigel Birks (Healthcare Specialist Sales) Harriet Ward (Corporate Broking) Michael F Johnson (Sales)

About IXICO www.IXICO.com

IXICO is a global leader in neuroscience imaging and biomarker analytics, using its proprietary AI-driven platform to help advance the treatment of neurological disorders and reduce the uncertainties associated with drug discovery, development and monitoring.   As a key part of the global neurological disease research community, the Company has built a global reputation and 20-year track record as an end-to-end Imaging Contract Research Organisation (iCRO) working with leading pharma companies, innovative biotech's, disease consortia and non-profit organisations. IXICO has supported hundreds of neurological clinical trials, analysed hundreds of thousands scans and built an expansive network of expert imaging centres around the world.  

The IXICO Platform is tailor-made for neurological disease, reliably processing data from global trials, precisely measuring key imaging biomarkers associated with the identification, progression and treatment of diseases such as Alzheimer's, Huntington's and Parkinson's.  Image data is interrogated by the Platform and IXICO's expert scientists translating complex data into clinically meaningful while minimizing data variability and increasing reproducibility.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCUOASRVWUARAA